Literature DB >> 33651357

Urinary Biomarkers In Bladder Cancer.

Matteo Costantini1, Graziana Gallo2, Giovanna Attolini2.   

Abstract

Bladder cancer has a very high frequency of recurrence and therefore requires close clinical surveillance throughout its life, with cystoscopies and serial cytological examinations. These tests are both invasive and expensive, with considerable interpersonal and inter-institutional variability. Moreover, cytological examination used for the diagnosis of low-grade tumors has a low sensitivity; thus, there is an increasing focus on the research for new, accurate, urinary markers. Herein, the biological basis, methodologies, and diagnostic performance of biomarkers are discussed.

Entities:  

Keywords:  BTA; Detection; FISH; Immunocyt; Molecular diagnosis; NMP-22; Surveillance; Urinary biomarker; Urinary bladder cancer; UroVysion

Mesh:

Substances:

Year:  2021        PMID: 33651357     DOI: 10.1007/978-1-0716-1354-2_11

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Nuclear matrix protein 22 for bladder cancer detection: comparative analysis of the BladderChek® and ELISA.

Authors:  Georgios Hatzichristodoulou; Hubert Kübler; Hartwig Schwaibold; Stefan Wagenpfeil; Cornelia Eibauer; Christian Hofer; Jürgen Gschwend; Uwe Treiber
Journal:  Anticancer Res       Date:  2012-11       Impact factor: 2.480

2.  Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.

Authors:  Hassan Jamshidian; Kianoush Kor; Mahmoud Djalali
Journal:  Urol J       Date:  2008       Impact factor: 1.510

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.